Annovis Bio, Inc. (NYSE: ANVS)

Sector: Healthcare Industry: Biotechnology CIK: 0001477845
Market Cap 42.61 Mn
P/B 3.24
P/E -1.71
P/S 0.00
ROIC (Qtr) -169.75
Div Yield % 0.00
Rev 1y % (Qtr) 0.00
Total Debt (Qtr) 0.00
Debt/Equity (Qtr) 0.00
Add ratio to table...

About

Annovis Bio, Inc., a clinical-stage drug platform company, is dedicated to addressing neurodegeneration, including Alzheimer's disease (AD) and Parkinson's disease (PD). The company's primary stock symbol is BNC. Annovis Bio operates in the pharmaceutical industry, specifically within the neurodegenerative disease market. Annovis Bio's main business activities involve the development of a drug platform targeting neurodegeneration. Their operations span across multiple countries, including the United States. The company's leadership team boasts...

Read more

Investment thesis

Bull case

  • Tangible assets of 17.19M provide robust 10.60x coverage of other current liabilities 1.62M, indicating strong asset backing.
  • Cash reserves of 15.29M provide solid 51.13x coverage of other non-current liabilities 299000, indicating strong liquidity.
  • Strong cash position of 15.29M provides 9.43x coverage of other current liabilities 1.62M, indicating excellent liquidity.
  • Cash reserves of 15.29M provide robust 4.09x coverage of current liabilities 3.73M, indicating strong short-term solvency.
  • Cash position of 15.29M represents healthy 1.14x of working capital 13.46M, demonstrating strong operational liquidity.

Bear case

  • Investment activities of 0 provide weak support for R&D spending of 21.46M, which is 0x, suggesting potentially insufficient investment in innovation relative to other capital deployment.
  • The company's operating cash flow of (24.98M) shows concerning coverage of stock compensation expenses of 2.92M, with a -8.54 ratio indicating potential earnings quality issues.
  • High financing cash flow of 27.63M relative to working capital of 13.46M, which is 2.05x suggests concerning dependence on external funding for operational needs.
  • Operating cash flow of (24.98M) is outpaced by equity issuance of 27.63M (-0.90 ratio), indicating concerning reliance on equity markets for funding operations.
  • Tangible assets of 17.19M provide limited backing for working capital of 13.46M, which is 1.28x, suggesting increased operational risk in market downturns.

Peer comparison

Companies in the Biotechnology
S.No. Ticker Company Market Cap P/E P/S Total Debt (Qtr)
1 SMMT Summit Therapeutics Inc. 1,204.25 Bn -1,306.67 0.00 0.01 Bn
2 ONC BeOne Medicines Ltd. 486.51 Bn 7,097.20 97.84 1.90 Bn
3 VRTX Vertex Pharmaceuticals Inc / Ma 122.05 Bn 30.87 10.17 1.85 Bn
4 REGN Regeneron Pharmaceuticals, Inc. 83.00 Bn 18.42 5.79 2.71 Bn
5 ARGX Argenx Se 50.78 Bn 33.71 26,480.10 -
6 ALNY Alnylam Pharmaceuticals, Inc. 43.66 Bn 139.17 11.76 2.97 Bn
7 BNTC Benitec Biopharma Inc. 43.61 Bn -941.82 0.00 0.00 Bn
8 INSM INSMED Inc 28.88 Bn -24.40 64.61 0.74 Bn

Industry comparisons

Current Valuation Value Ind Avg Percentile
EV to Assets EV to Assets 1.48 11.06
EV to Cash from Ops. EV/CFO -1.02 26.32
EV to Debt EV to Debt 0.00 762.61
EV to EBIT EV/EBIT -1.02 -13.49
EV to EBITDA EV/EBITDA -0.95 8.61
EV to Free Cash Flow [EV/FCF] EV/FCF -1.02 25.66
EV to Market Cap EV to Market Cap 0.60 203.37
EV to Revenue EV to Revenue 0.00 156.31
Price to Book Value [P/B] P/B 3.24 20.59
Price to Earnings [P/E] P/E -1.71 -0.88
Dividend Metrics Value Ind Avg Percentile
Dividend Coverage Ratio Dividend Coverage Ratio 0.00 -12.64
Dividend Payout Ratio % Div Payout % (Qtr) 0.00 0.17
Dividend per Basic Share Div per Share (Qtr) 0.00 0.01
FCF Dividend Payout Ratio % FCF Div Payout % (Qtr) 0.00 -0.14
Interest Coverage Int. cover (Qtr) 0.00 956.66
Growth Metrics Value Ind Avg Percentile
Capex Growth (1y) % Capex Growth (1y) % 0.00 7.87
Cash and Equivalents Growth (1y) % Cash & Equiv 1y % (Qtr) 20.97 753.48
Dividend Growth (1y) % Dividend Growth (1y) % 0.00 0.01
EBIAT Growth (1y) % EBIAT 1y % (Qtr) 39.22 -57.63
EBITDA Growth (1y) % EBITDA 1y % (Qtr) 12.10 8.83
EBIT Growth (1y) % EBIT 1y % (Qtr) 39.22 -67.21
EBT Growth (1y) % EBT 1y % (Qtr) 39.22 -23.74
EPS Growth (1y) % EPS 1y % (Qtr) 63.80 -7.02
FCF Growth (1y) % FCF 1y % (Qtr) -8.72 -40.48
Gross Profit Growth (1y) % Gross Profit Growth (1y) % 0.00 264.51
Liquidity Ratios Value Ind Avg Percentile
Asset Utilization Ratio Asset Util Ratio (Qtr) 0.00 0.14
Cash Payout Ratio Cash Payout (Qtr) 0.00 0.00
Cash Ratio Cash Ratio (Qtr) 4.09 3.92
Current Ratio Curr Ratio (Qtr) 4.60 7.33
Debt to Equity Ratio Debt/Equity (Qtr) 0.00 0.48
Interest Cover Ratio Int Coverage (Qtr) 0.00 956.66
Times Interest Earned Times Interest Earned (Qtr) 0.00 956.66
Profitability Value Ind Avg Percentile
EBITDA Margin % EBITDA Margin % 0.00 -17,888.70
EBIT Margin % EBIT Margin % 0.00 -18,246.34
EBT Margin % EBT Margin % 0.00 -19,108.08
Gross Margin % Gross Margin % 0.00 -10.30
Net Profit Margin % Net Profit Margin % 0.00 -19,056.96